Baroldi Joseph 4

4 · IONIS PHARMACEUTICALS INC · Filed Apr 17, 2026

AI-generated summary of this filing

Updated Apr 17, 2026

Ionis (IONS) EVP Joseph Baroldi Receives RSUs, Sells Shares

What Happened

Joseph Baroldi, EVP & Chief Business Officer of Ionis Pharmaceuticals (IONS), had 10,837 restricted stock units (RSUs) vest and convert into 10,837 shares on 2026-04-15 (reported as a derivative conversion, code M) at no purchase price. On 2026-04-16 he sold 5,619 of those shares in the open market (code S) for a weighted average price of $74.56, generating proceeds of approximately $418,953. The sale was an automatic sale-to-cover tax withholding obligations tied to the RSU vesting.

Key Details

Transaction dates: RSU conversion 2026-04-15; open-market sale 2026-04-16; Form 4 filed 2026-04-17 (appears timely).
RSU conversion: 10,837 shares acquired at $0.00 (conversion of vested RSUs).
Sale: 5,619 shares disposed at a weighted average price of $74.56; reported price range $74.12–$75.01. Footnote indicates the filer can provide per-price breakdown on request.
Reason for sale: Footnote states the sale was an automatic sale to cover required tax withholding under the company’s 2011 Equity Incentive Plan.
RSU terms: Each RSU equals one share; RSUs vest in four equal annual installments and are paid in shares or cash per plan (footnotes F4–F5).
Shares owned after the transactions are not specified in the provided Form 4.

Context

This was mainly a routine award vesting (not a market purchase) with a partial sale to satisfy tax withholding — a common administrative transaction that doesn’t necessarily signal a change in insider sentiment. The RSU conversion (code M) and subsequent sale-to-cover are standard; no 10b5-1 plan or late filing is indicated in the provided information.

Form 4

Period: 2026-04-15

EVP, Chief Business Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-04-15+10,837→ 52,154 total
Sale
Common Stock
[F2][F3]
2026-04-16$74.56/sh−5,619$418,953→ 46,535 total
Exercise/Conversion
Restricted Stock Unit
[F4][F5]
2026-04-15−10,837→ 48,312 total
Exercise: $0.00From: 2026-04-15→ Common Stock (10,837 underlying)

Holdings

Footnotes (5)

[F1]Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.
[F2]The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.12 to $75.01 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
[F4]Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
[F5]Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

Signature

By: Patrick R. O'Neil, attorney-in-fact For: Joseph T. Baroldi|2026-04-17

1 file